Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database

Background: Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age. Methods: Women who initiated a treatment for HER2+ MBC between 2008 and 20...

Full description

Bibliographic Details
Main Authors: Mylène Annonay, MD, Lisa Gauquelin, MD, Romain Geiss, MD, Mony Ung, MD, Laurence Cristol-Dalstein, MD, Marie-Ange Mouret-Reynier, MD PHD, Anthony Goncalves, MD PHD, Sophie Abadie-Lacourtoisie, MD, Eric Francois, MD, Christophe Perrin, MD, Johan Le Fel, MD, Véronique Lorgis, MD, Véronique Servent, MD, Lionel Uwer, MD, Christelle Jouannaud, MD, Marianne Leheurteur, MD, Florence Joly, MD PHD, Loic Campion, MD, Coralie Courtinard, MPH, Olivier Villacroux, MD, Thierry Petit, MD PHD, Pierre Soubeyran, MD, Catherine Terret, MD, Carine Bellera, PHD, Etienne Brain, MD PHD, Suzette Delaloge, MD MPH
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Breast
Subjects:
Metastatic breast cancer
Overall survival
Elderly
HER2
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621004689

Internet

http://www.sciencedirect.com/science/article/pii/S0960977621004689

Similar Items